BRPI0809137A2 - métodos de diagnosticar, câncer endometrial e pré-câncer classificar e tratar - Google Patents

métodos de diagnosticar, câncer endometrial e pré-câncer classificar e tratar

Info

Publication number
BRPI0809137A2
BRPI0809137A2 BRPI0809137A BRPI0809137A BRPI0809137A2 BR PI0809137 A2 BRPI0809137 A2 BR PI0809137A2 BR PI0809137 A BRPI0809137 A BR PI0809137A BR PI0809137 A BRPI0809137 A BR PI0809137A BR PI0809137 A2 BRPI0809137 A2 BR PI0809137A2
Authority
BR
Brazil
Prior art keywords
precancer
classify
diagnosing
treat
methods
Prior art date
Application number
BRPI0809137A
Other languages
English (en)
Inventor
Pamela Pollock
Paul Goodfellow
Original Assignee
Translational Genomics Res Inst
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Translational Genomics Res Inst, Univ Washington filed Critical Translational Genomics Res Inst
Publication of BRPI0809137A2 publication Critical patent/BRPI0809137A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57442—Specifically defined cancers of the uterus and endometrial
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Food Science & Technology (AREA)
  • Reproductive Health (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
BRPI0809137A 2007-03-23 2008-03-24 métodos de diagnosticar, câncer endometrial e pré-câncer classificar e tratar BRPI0809137A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US89688407P 2007-03-23 2007-03-23
US98209307P 2007-10-23 2007-10-23
PCT/US2008/058065 WO2008118877A2 (en) 2007-03-23 2008-03-24 Method of diagnosing, classifying and treating endometrial cancer and precancer

Publications (1)

Publication Number Publication Date
BRPI0809137A2 true BRPI0809137A2 (pt) 2016-07-26

Family

ID=39789252

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0809137A BRPI0809137A2 (pt) 2007-03-23 2008-03-24 métodos de diagnosticar, câncer endometrial e pré-câncer classificar e tratar

Country Status (12)

Country Link
US (1) US20100111944A1 (pt)
EP (1) EP2132331B1 (pt)
JP (1) JP2010525301A (pt)
KR (1) KR20100015883A (pt)
CN (1) CN101903534B (pt)
AU (1) AU2008230880B2 (pt)
BR (1) BRPI0809137A2 (pt)
CA (1) CA2680046A1 (pt)
ES (1) ES2600882T3 (pt)
HK (1) HK1151321A1 (pt)
IL (1) IL200908A (pt)
WO (1) WO2008118877A2 (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2336832T3 (es) 2005-07-22 2010-04-16 Five Prime Therapeutics, Inc. Composiciones y procedimientos para tratar enfermedades con proteinas de fusion de fgfr.
BRPI0916904A2 (pt) 2008-08-04 2016-10-11 Fiveprime Therapeutics Inc polipeptídeos, moléculares de fusão ecd fgfr4, composições farmacêuticas, polinucleotídio e métodos de tratamento de desordem angiogênica, câncer em paciente e degeneração macular em paciente e respectivos usos
KR101699432B1 (ko) * 2008-11-07 2017-01-24 갤럭시 바이오테크, 엘엘씨 섬유아세포성장인자수용체 ２에 대한 모노클로날 항체
KR20120089838A (ko) * 2009-07-17 2012-08-14 더 트랜스내셔날 게노믹스 리서치 인스티튜트 암 위험성 평가에 사용되는 방법 및 키트
WO2011034940A1 (en) 2009-09-15 2011-03-24 Five Prime Therapeutics, Inc. Hair growth methods using fgfr4 extracellular domains
ES2600631T3 (es) * 2009-11-13 2017-02-10 Five Prime Therapeutics, Inc. Uso de proteínas del dominio extracelular de FGFR1 para tratar cánceres caracterizados por mutaciones activadoras dependientes de ligando en FGFR2
WO2011084711A2 (en) 2009-12-17 2011-07-14 Five Prime Therapeutics, Inc. Hair growth methods using fgfr3 extracellular domains
EP2547698B1 (en) * 2010-03-14 2015-07-29 The Translational Genomics Research Institute Methods of determining susceptibility of tumors to tyrosine kinase inhibitors
NZ603972A (en) * 2010-05-11 2014-11-28 Aveo Pharmaceuticals Inc Anti-fgfr2 antibodies
US8481038B2 (en) 2010-11-15 2013-07-09 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
US8951972B2 (en) 2010-12-09 2015-02-10 Five Prime Therapeutics, Inc. FGFR1 extracellular domain combination therapies for lung cancer
DK3246416T3 (da) 2011-04-15 2024-09-02 Univ Johns Hopkins Sikkert sekventeringssystem
US20130136740A1 (en) 2011-11-14 2013-05-30 Thomas Harding Methods of treating cancer
CN109457030B (zh) * 2012-10-29 2022-02-18 约翰·霍普金斯大学 卵巢和子宫内膜癌的帕帕尼科拉乌测试
US20140278133A1 (en) * 2013-03-15 2014-09-18 Advanced Throughput, Inc. Systems and methods for disease associated human genomic variant analysis and reporting
DK3708583T3 (da) 2013-08-01 2022-05-16 Five Prime Therapeutics Inc Ikke-fucosylerede anti-fgfr2iiib-antistoffer
CN103937798B (zh) * 2014-04-23 2016-06-01 西安交通大学医学院第一附属医院 一种与子宫内膜癌相关的长非编码RNA及其siRNA和应用
AU2016300175A1 (en) * 2015-07-24 2018-03-01 Debiopharm International Sa FGFR expression and susceptibility to an FGFR inhibitor
US11286531B2 (en) 2015-08-11 2022-03-29 The Johns Hopkins University Assaying ovarian cyst fluid
CN108368174B (zh) 2015-11-23 2023-04-14 戊瑞治疗有限公司 用于癌症治疗的单独fgfr2抑制剂或与免疫刺激剂的组合
CN107102141A (zh) * 2016-02-23 2017-08-29 中国科学院生物物理研究所 分子标记物cd71及在子宫内膜癌诊断、分期及预后中的应用
CN118416216A (zh) 2017-05-16 2024-08-02 戊瑞治疗有限公司 癌症治疗中抗fgfr2抗体与化学治疗剂的组合
JOP20190280A1 (ar) * 2017-06-02 2019-12-02 Janssen Pharmaceutica Nv مثبطات fgfr2 لعلاج سرطان الأوعية الصفراوية
CN111107881A (zh) * 2017-06-22 2020-05-05 密执安州立大学董事会 成纤维细胞生长因子受体2特异性肽试剂和方法
BR112020000926A2 (pt) * 2017-07-21 2020-07-21 Fundació Hospital Universitari Vall D'hebron - Institut De Recerca ctnb1 como um marcador para o câncer endometrial
CN113777312B (zh) * 2021-09-03 2024-02-02 普十生物科技(北京)有限公司 乙肝抗体片段的制备方法、乙肝抗体片段、试剂盒及应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5911776A (en) * 1996-12-18 1999-06-15 Unisys Corporation Automatic format conversion system and publishing methodology for multi-user network
JP3623715B2 (ja) * 2000-04-07 2005-02-23 日本電気株式会社 通信端末装置
US6649359B2 (en) * 2000-06-01 2003-11-18 The Brigham & Women's Hospital, Inc. Diagnosis of endometrial precancers
US6901519B1 (en) * 2000-06-22 2005-05-31 Infobahn, Inc. E-mail virus protection system and method
US7263561B1 (en) * 2001-08-24 2007-08-28 Mcafee, Inc. Systems and methods for making electronic files that have been converted to a safe format available for viewing by an intended recipient
KR100493460B1 (ko) * 2002-08-29 2005-06-07 재단법인서울대학교산학협력재단 암 세포에서 발현되는 ｆｇｆｒ2 이성체
US7659062B2 (en) * 2003-06-03 2010-02-09 The Board of Trustee of the University of Arkansas System Gene expression profiling of uterine serous papillary carcinomas and ovarian serous papillary tumors
WO2005066211A2 (en) * 2003-12-19 2005-07-21 Five Prime Therapeutics, Inc. Fibroblast growth factor receptors 1, 2, 3, and 4 as targets for therapeutic intervention
US7660999B2 (en) * 2004-06-22 2010-02-09 Microsoft Corporation MIME handling security enforcement
US7228307B2 (en) * 2004-07-29 2007-06-05 International Business Machines Corporation Security model using security domains in a security model applied to abstract database
US20090220495A1 (en) * 2005-04-07 2009-09-03 Abdallah Fanidi Cancer Related Genes (PRLR)

Also Published As

Publication number Publication date
JP2010525301A (ja) 2010-07-22
AU2008230880B2 (en) 2014-04-24
ES2600882T3 (es) 2017-02-13
KR20100015883A (ko) 2010-02-12
US20100111944A1 (en) 2010-05-06
EP2132331A4 (en) 2010-04-21
HK1151321A1 (en) 2012-01-27
AU2008230880A1 (en) 2008-10-02
CN101903534A (zh) 2010-12-01
IL200908A (en) 2014-03-31
WO2008118877A8 (en) 2009-10-29
IL200908A0 (en) 2010-05-17
EP2132331A2 (en) 2009-12-16
CA2680046A1 (en) 2008-10-02
WO2008118877A2 (en) 2008-10-02
WO2008118877A3 (en) 2008-12-24
EP2132331B1 (en) 2016-08-03
CN101903534B (zh) 2014-07-30

Similar Documents

Publication Publication Date Title
BRPI0809137A2 (pt) métodos de diagnosticar, câncer endometrial e pré-câncer classificar e tratar
NL301192I2 (nl) Finerenon en zijn zouten, solvaten en solvaten van de zouten daarvan
CR10667A (es) Compositions and methods for diagnosing and treating cancer
BRPI0921321A2 (pt) métodos para o tratamento de indwcções e tumores
BRPI0718850A2 (pt) Métodos de tratar, diagnosticar ou detectar câncer
EP2147124A4 (en) EPIGENETIC BIOMARKERS FOR EARLY DETECTION, EFFICIENT TREATMENT AND RETENTION OF CANCER
BRPI0810206A2 (pt) Método de tratar câncer
BRPI0813212A2 (pt) Métodos de tratamento de doenças e distúrbios mediados por serotonina
BRPI0813364A2 (pt) Métodos de diagnóstico e tratamento de câncer.
BRPI0818320A2 (pt) composição para tratamento de câncer de próstata (pca)
BRPI0814330A2 (pt) métodos e kits cirúrgicos
BRPI0924069A2 (pt) métodos de diagnosticar e tratar disfagia
BRPI0911998A2 (pt) métodos e kits para o tratamento de condições de desordem inflamatória intestinal
IL190870A0 (en) Methods for prediction and prognosis of cancer, and monitoring cancer therapy
ZA200803430B (en) Methods for prediction and prognosis of cancer, and monitoring cancer therapy
WO2010017515A3 (en) Breast cancer specific markers and methods of use
HK1153273A1 (en) Cancer diagnosis based on levels of antibodies against globo h and its fragments globo h
BRPI0906975A2 (pt) Escova de dente para o tratamento e/ou detecção de micróbios
BRPI0919238A2 (pt) métodos e composições para o tratamento de câncer
BR112012004281A2 (pt) uso de metformina tratamento e prevenção de câncer
BRPI1008564A2 (pt) métodos e composições para o dignóstico e tratamento de câncer
ZA200803516B (en) Methods for prediction and prognosis of cancer, and monitoring cancer therapy
BRPI1007995A2 (pt) orto-aminoamidas para o tratamento de cãncer.
BR112013012072A2 (pt) derivados, composições de benzodiazepina e métodos para o tratamento de danos cognitivos
DK2147122T3 (da) Enzymatisk kræftbehandling

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 4A, 5A, 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]